Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001823747 XXXXXXXX LIVE 4 Ordinary Shares, Nominal value 0.12 per share 08/08/2025 false 0001936258 N62509109 NewAmsterdam Pharma Company N.V. Gooimeer 2-35 Naarden P7 1411 DC Forbion Capital Partners 31 (0) 35 699 30 00 Gooimeer 2-35 Naarden P7 1411 DC 0001823747 N Forbion Capital Fund IV Cooperatief U.A. b WC N P7 0 5930781 0 5930781 5930781 N 5.3 OO Y Forbion IV Management B.V. b AF N P7 0 5930781 0 5930781 5930781 N 5.3 OO Y Forbion Growth Opportunities Fund I Cooperatief U.A. b WC N P7 0 4648025 0 4648025 4648025 N 4.1 OO Y Forbion Growth Management B.V. b AF N P7 0 4648025 0 4648025 4648025 N 4.1 OO Y ForGrowth NAP B.V. b WC AF N P7 0 10578806 0 10578806 10578806 N 9.4 OO Ordinary Shares, Nominal value 0.12 per share NewAmsterdam Pharma Company N.V. Gooimeer 2-35 Naarden P7 1411 DC This Amendment No. 4 ("Amendment No. 4") amends and supplements the Schedule 13D originally filed on June 30, 2023, as amended from time to time (the "Schedule 13D") relating to the ordinary shares (the "Ordinary Shares"), nominal value 0.12 per share, of NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze vennotschap) incorporated under the laws of the Netherlands (the "Issuer"). Capitalized terms used herein and not otherwise defined shall have the same meanings ascribed to them in the Schedule 13D. (i) Forbion Growth I may be deemed to beneficially own 4,648,025 Ordinary Shares held through ForGrowth, representing approximately 4.1% of the outstanding Ordinary Shares, (ii) Forbion IV may be deemed to beneficially own 5,930,781 Ordinary Shares held through ForGrowth, representing approximately 5.3% of the of the outstanding Ordinary Shares and (iii) ForGrowth may be deemed to beneficially own 10,578,806 Ordinary Shares, representing approximately 9.4% of the outstanding Ordinary Shares, including an aggregate of 9,926,633 Ordinary Shares allocable to Forbion Growth I and Forbion IV through ForGrowth's interest in PoolCo. Forbion Growth Management may be deemed to beneficially own the Ordinary Shares that may be deemed to be beneficially owned by Forbion Growth I, and Forbion IV Management may be deemed to beneficially own the Ordinary Shares that may be deemed to be beneficially owned by Forbion IV. The percentage of the outstanding Ordinary Shares that may be deemed to be beneficially owned by the Reporting Persons is based upon 112,628,458 shares of the Issuer's Ordinary Shares outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2025. See above. Information concerning transactions in the Ordinary Shares of the Issuer effected since the most recent filing of Schedule 13D is set forth in Annex I of this Schedule 13D. Not applicable. Not applicable. Forbion Capital Fund IV Cooperatief U.A. /s/ V. van Houten /s/ G.J. Mulder V. van Houten and G.J. Mulder, Directors of its Director 08/12/2025 Forbion IV Management B.V. /s/ V. van Houten /s/ G.J. Mulder V. van Houten and G.J. Mulder, Directors 08/12/2025 Forbion Growth Opportunities Fund I Cooperatief U.A. /s/ V. van Houten /s/ G.J. Mulder V. van Houten and G.J. Mulder, Directors of its Director 08/12/2025 Forbion Growth Management B.V. /s/ V. van Houten /s/ G.J. Mulder V. van Houten and G.J. Mulder, Directors 08/12/2025 ForGrowth NAP B.V. /s/ V. van Houten /s/ G.J. Mulder V. van Houten and G.J. Mulder, Directors of its Director 08/12/2025